Abstract: Disclosed are improved topical compositions having improved efficiency such as improved sunscreen effectiveness for protecting the skin from the harmful effects of ultraviolet irradiation, such as sunburn and sun-induced premature aging of the skin.

Abstract: Disclosed are medicated cleansing pads comprising:(a) from about 50% to about 75% of two or more layers of nonwoven fabric materials;(b) from about 20% to about 75% (on a dry solids basis) of a water soluble polymeric resin of the formula: ##STR1## wherein A is one or more monomers selected from styrene or styrene derivatives and B is one or more monomers selected from butadiene or butadiene derivatives, x is the number of different A monomer components present in the copolymer chain, with x being an integer of 1 or more and y is the number of B monomer components present in the copolymer chain, with y being an integer of 0 or more and m:n is the weight ratio of A monomer components to B monomer components, and is from about 10:1 to about 1:5; and(c) from about 0.1% to about 50.0% of a salicylic acid active composition.This invention also encompasses a method of treating acne in humans and lower animals comprising topically applying to the affected area the medicated pads of the present invention.

Abstract: Disclosed are medicated cleansing pads comprising: (a) from about 50% to about 75% of a nonwoven fabric material; (b) from about 20% to about 75% (on a dry solids basis) of a water soluble polymeric resin of the formula:(A.sub.x).sbsb.m (B.sub.y).sbsb.nwherein A is one or more monomers selected from styrene or styrene derivatives and B is one or more monomers selected from butadiene or butadiene derivatives, x is the number of different A monomer components present in the copolymer chain, with x being an integer of 1 or more and y is the number of B monomer components present in the copolymer chain, with y being an integer of 0 or more and m:n is the weight ratio of A monomer components to B monomer components, and is from about 10:1 to about 1:5, preferably from about 5:1 to about 1:2, and (c) from about 0.1% to about 50% of salicylic acid active composition.